Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Denali Therapeutics Inc
(NQ:
DNLI
)
15.56
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
15.56
Bid (Size)
15.50 (1)
Ask (Size)
16.86 (3)
Prev. Close
15.56
Today's Range
15.56 - 15.56
52wk Range
15.45 - 33.31
Shares Outstanding
121,640,069
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
To the Moon and Beyond: 7 Stocks With Cosmic Potential
March 14, 2024
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.
Via
InvestorPlace
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
February 29, 2024
Via
Benzinga
Performance
YTD
-27.26%
-27.26%
1 Month
-21.69%
-21.69%
3 Month
-9.06%
-9.06%
6 Month
-20.77%
-20.77%
1 Year
-35.06%
-35.06%
More News
Read More
4 Analysts Assess Denali Therapeutics: What You Need To Know
February 28, 2024
Via
Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
February 27, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Denali Therapeutics: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
The Latest Analyst Ratings for Denali Therapeutics
December 13, 2023
Via
Benzinga
Where Denali Therapeutics Stands With Analysts
November 08, 2023
Via
Benzinga
Analyst Expectations for Denali Therapeutics's Future
August 31, 2023
Via
Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Via
Benzinga
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
February 27, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Where Denali Therapeutics Stands With Analysts
August 10, 2023
Via
Benzinga
Denali Therapeutics Announces $500 million Private Placement Equity Financing
February 27, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
February 12, 2024
Via
Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
February 08, 2024
Via
InvestorPlace
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
February 07, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
February 01, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 08, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
January 02, 2024
Via
InvestorPlace
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 07, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
November 03, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
September 06, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
August 30, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
June 29, 2023
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.